Actively Recruiting
Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.
Led by Tata Memorial Centre · Updated on 2025-04-09
30
Participants Needed
1
Research Sites
515 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical study is going to be done on a type of brain tumor in children called Medulloblastoma. The WNT pathway type of medulloblastoma is considered to be low risk and have the best outcomes in terms of survival. With the current standard of care for this type of medulloblastoma it is believed by the investigators that we are over treating the disease and increasing the long term side effects of these children. Several groups in the world are testing de-intensification of treatment in this favourable subset of children who experience long term late side effects of therapy. By reducing the dose to the craniospinal axis and keeping the total tumor bed dose the same in this study the investigators are expecting to reduce some of the late side effects of craniospinal irradiation without compromising disease control and survival.
CONDITIONS
Official Title
Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age more than 3 years and less than 16 years.
- Newly diagnosed WNT pathway medulloblastoma.
- Post-surgery residual disease less than 1.5 cm2 on post-operative MRI brain.
- No evidence of metastatic disease in the brain, spine or cerebrospinal fluid.
- Fit for initiation of adjuvant treatment within 6 weeks of surgery.
You will not qualify if you...
- Age less than 3 years or more than 16 years.
- Molecular subgroup other than WNT pathway.
- Post-surgery residual disease more than 1.5 cm2 on post-operative imaging.
- Evidence of metastatic disease in the brain, spine, or cerebrospinal fluid.
- Previous history of radiotherapy or chemotherapy before study enrollment.
- Not fit to start adjuvant treatment within 6 weeks of surgery.
- Not willing to provide consent or assent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tata Memorial Hospital
Mumbai, Maharashtra, India, 400012
Actively Recruiting
Research Team
T
Tejpal Dr Gupta, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here